Clinical Trials: Renal Cell Cancer

Arizona

Scottsdale; Premeiere Oncology of Arizona
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Arkansas

Hot Springs; Genesis Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

California

Duarte; City of Hope
The High-Dose Aldesleukin (IL-2) Select Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Metastatic Renal Cell Carcinoma

Duarte; City of Hope
A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First Line Therapy for Metastatic Renal Cell Cancer (Renal Effect Trial)

San Francisco; California Kidney Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Colorado

Denver; Rocky Mountain Cancer Centers
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Connecticut

Greenwich; Bendheim Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Florida

Boca Raton; The Center for Hematology - Oncology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Fort Lauderdale; Bienes Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Gainesville; Gainesville Hematology Oncology Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Lakeland; Lakeland Regional Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Orlando; M.D. Anderson Cancer Center Orlando
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

West Palm Beach; Palm Beach Cancer Institute
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Georgia

Augusta; Augusta Oncology Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Augusta; Medical Oncology Associates of Augusta PC
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Idaho

Boise; St. Luke's Mountain States Tumor Instiutue (MSTI)
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Indiana

South Bend; Northern Indiana Cancer Research Center Consortium
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Kentucky

Louisville; Louisville Oncology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Louisiana

Baton Rouge; Louisiana Hematology Oncology at Mary Bird Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Metarie; Hematology and Oncology Specialists
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Maryland

Baltimore; Division of Surgical Oncology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Bethesda; Center for Cancer and Blood Disorders
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Michigan

Grand Rapids; Cancer and Hematology Centers of Western Michigan
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Missouri

St. Louis; St. John’s Mercy, David C. Pratt Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Nevada

Las Vegas; Nevada Cancer Institute
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Las Vegas; Comprehensive Cancer Centers of NV
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

New Jersey

Hackensack; David Joseph Jurist Research Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

New Mexico

Farmington; San Juan Oncology Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

New York

Albany; New York Oncology Hematology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Rochester; Interlakes Foundation, Inc.
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

North Carolina

Hickory; Northwestern Carolina Oncology and Hematology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Raleigh; Raleigh Hematology Oncology Associates, P.C.
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Ohio

Canton; Gabrail Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Columbus; Mid Ohio Oncology/Hematology, Inc.
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Oklahoma

Oklahoma City; Cancer Care Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Tulsa; Cancer Care Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Oregon

Eugene; Oncology Associates of Oregon
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Pennsylvania

Dunmore; Hematology & Oncology Associates of Northeastern PA
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Lemoyne; Central Pennsylvania Hematology & Oncology Associates, PC
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

South Carolina

Greenville; Eastside Medical Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Texas

Austin; Southwest Regional Cancer Center, Research Department
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Austin; Texas Oncology Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Bedford; Texas Oncology, PA
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Corpus Christi; Coastal Bend Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer

Dallas; Texas Oncology, PA
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Dallas; Center for Oncology Research and Treatment, P.A.
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

El Paso; El Paso Cancer Treatment Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

San Antonio; South Texas Oncology and Hematology
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Tyler; Tyler Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Webster; Deke Slayton Cancer Center
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Virginia

Newport News; Peninsula Cancer Institute
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

Norfolk; Virginia Oncology Associates
Phase 2 study of sunitinib malate schedule 4/2 (4 weeks on treatment, 2 weeks off treatment cycle) vs. sunitinib malate continuous dosing for metastatic renal cell cancer.

International

Adelaide, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Brisbane, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Canberra, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Frankston, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Melbourne, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Perth, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Sydney, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Antwerpen, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Bruxelles, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Wilrijk, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Ceské Budejovice, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Chomutov, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Hradec Kralove, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Plzen, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Tampere, Finland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Turku, Finland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Angers, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Bordeaux, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Caen, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Clermont-Ferrand, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Grenoble, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Lille, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Limoges, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Lyon, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Marseille, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Nice, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Poitiers, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Saint Herblain, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Strasbourg, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Suresnes, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Toulouse, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Villejuif, France; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Berlin, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Berlin, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Bonn, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Bremen, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Cottbus, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Darmstadt, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Darmstadt, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Dessau, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Düsseldorf, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Erlangen, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Frankfurt Am Main, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Göttingen, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Greifswald, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Halle, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Hamburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Hannover, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Hannover, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Homburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Jena, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Kassel, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Kiel, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Leipzig, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Lübeck, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Magdeburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Mainz, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Mannheim, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Marburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Marburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

München, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

München, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Neuss, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Planegg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Rehling, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Stuttgart, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Ulm, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Villingen-Schwenningen, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Weiden, Germany; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Budapest, Hungary; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Szombathely, Hungary; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Holon, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Ramat Gan, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Rehovot, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Tel Aviv, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Zerifin, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Livorno, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Milano, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Modena, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Napoli, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Perugia, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Roma, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Rozzano, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Torino, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Amsterdam, Netherlands; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Nijmegen, Netherlands; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Ċlesund, Norway; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Oslo, Norway; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Stavanger, Norway; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Trondheim, Norway; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Bydgoszcz, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Krakow, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Lodz, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Olsztyn, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Tarnow, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Warszawa, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Moscow, Russian Federation; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Obninsk, Russian Federation; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

St Petersburg, Russian Federation; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Singapore, Singapore; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Barcelona, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Granada, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Madrid, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Malaga, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Pontevedra, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Santander, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Valencia, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Zaragoza, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Basel, Switzerland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Bern, Switzerland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Geneve, Switzerland; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Chang Gung, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Kaohsiung, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Taichung, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Taipei, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

London, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Manchester, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy